Last10K.com

Marina Biotech, Inc. (MRNA) SEC Filing 10-Q Quarterly report for the period ending Friday, March 31, 2017

Adhera Therapeutics, Inc.

CIK: 737207
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2017
May 15, 2017
Document And Entity Information  
Entity Registrant NameMarina Biotech, Inc. 
Entity Central Index Key0000737207 
Document Type10-Q 
Document Period End DateMar. 31, 2017 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Filer CategorySmaller Reporting Company 
Entity Common Stock, Shares Outstanding 97,169,153
Trading SymbolMRNA 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2017 

View differences made from one quarter to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..

Continue

Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets (unaudited) (parenthetical)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Changes In Equity (capital Deficiency) (unaudited)
Condensed Consolidated Statements Of Operations (unaudited)
Commitments And Contingencies
Intangible Assets
Intangible Assets (details Narrative)
Intangible Assets (tables)
Intangible Assets - Schedule Of Intangible Assets (details)
Intellectual Property And Collaborative Agreements
Intellectual Property And Collaborative Agreements (details Narrative)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies (details Narrative)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies (policies)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies (tables)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Anti-dilutive Securities (details)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Fair Value Liability Of Price Adjustable Warrants Determined By Level 3 (details)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Liabilities Measured At Fair Value On A Recurring Basis (details)
Notes Payable
Notes Payable (details Narrative)
Organization And Business Operations - Schedule Estimate Of Fair Value Of Assets Acquired And Liabilities (details)
Organization And Business Operations - Schedule Merger Agreement Based On Common Stock Outstanding (details)
Related Party Transactions
Related Party Transactions (details Narrative)
Stock Incentive Plans
Stock Incentive Plans (details Narrative)
Stock Incentive Plans (tables)
Stock Incentive Plans - Schedule Of Stock Option Activity (details)
Stock Incentive Plans - Schedule Of Summary Of Additional Information On Stock Options Outstanding (details)
Stockholders' Equity
Stockholders' Equity (details Narrative)
Stockholders' Equity (tables)
Stockholders??? Equity - Schedule Of Warrant Activity (details)
Subsequent Events
Subsequent Events (details Narrative)

Material Contracts, Statements, Certifications & more

Adhera Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

CIK: 737207
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-17-005362
Submitted to the SEC: Mon May 15 2017 5:11:10 PM EST
Accepted by the SEC: Mon May 15 2017
Period: Friday, March 31, 2017
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/737207/0001493152-17-005362.htm